171 related articles for article (PubMed ID: 1649576)
21. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Larder BA; Kemp SD; Harrigan PR
Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
[TBL] [Abstract][Full Text] [Related]
22. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.
Coates JA; Cammack N; Jenkinson HJ; Mutton IM; Pearson BA; Storer R; Cameron JM; Penn CR
Antimicrob Agents Chemother; 1992 Jan; 36(1):202-5. PubMed ID: 1590690
[TBL] [Abstract][Full Text] [Related]
23. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
Gobert JM; Remington KM; Zhu YQ; North TW
Antimicrob Agents Chemother; 1994 Apr; 38(4):861-4. PubMed ID: 8031060
[TBL] [Abstract][Full Text] [Related]
24. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
25. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
Mayers DL; Japour AJ; Arduino JM; Hammer SM; Reichman R; Wagner KF; Chung R; Lane J; Crumpacker CS; McLeod GX
Antimicrob Agents Chemother; 1994 Feb; 38(2):307-14. PubMed ID: 8192457
[TBL] [Abstract][Full Text] [Related]
26. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.
Richman D; Rosenthal AS; Skoog M; Eckner RJ; Chou TC; Sabo JP; Merluzzi VJ
Antimicrob Agents Chemother; 1991 Feb; 35(2):305-8. PubMed ID: 1708976
[TBL] [Abstract][Full Text] [Related]
27. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
Schinazi RF; Mellors J; Bazmi H; Diamond S; Garber S; Gallagher K; Geleziunas R; Klabe R; Pierce M; Rayner M; Wu JT; Zhang H; Hammond J; Bacheler L; Manion DJ; Otto MJ; Stuyver L; Trainor G; Liotta DC; Erickson-Viitanen S
Antimicrob Agents Chemother; 2002 May; 46(5):1394-401. PubMed ID: 11959574
[TBL] [Abstract][Full Text] [Related]
28. Metabolism and activities of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes.
Drake RR; McMasters R; Krisa S; Hume SD; Rechtin TM; Saylors RL; Chiang Y; Govindarajan R; Munshi NC
Antiviral Res; 1997 Aug; 35(3):177-85. PubMed ID: 9298757
[TBL] [Abstract][Full Text] [Related]
29. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides.
Van Draanen NA; Tisdale M; Parry NR; Jansen R; Dornsife RE; Tuttle JV; Averett DR; Koszalka GW
Antimicrob Agents Chemother; 1994 Apr; 38(4):868-71. PubMed ID: 7518218
[TBL] [Abstract][Full Text] [Related]
30. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
[TBL] [Abstract][Full Text] [Related]
31. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
Spector SA; Ripley D; Hsia K
Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
Rosowsky A; Fu H; Pai N; Mellors J; Richman DD; Hostetler KY
J Med Chem; 1997 Aug; 40(16):2482-90. PubMed ID: 9258355
[TBL] [Abstract][Full Text] [Related]
33. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
Kong XB; Zhu QY; Ruprecht RM; Watanabe KA; Zeidler JM; Gold JW; Polsky B; Armstrong D; Chou TC
Antimicrob Agents Chemother; 1991 Oct; 35(10):2003-11. PubMed ID: 1722077
[TBL] [Abstract][Full Text] [Related]
34. Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro.
Baba M; Ito M; Shigeta S; Tanaka H; Miyasaka T; Ubasawa M; Umezu K; Walker RT; De Clercq E
Antimicrob Agents Chemother; 1991 Jul; 35(7):1430-3. PubMed ID: 1929304
[TBL] [Abstract][Full Text] [Related]
35. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
Kemp SD; Shi C; Bloor S; Harrigan PR; Mellors JW; Larder BA
J Virol; 1998 Jun; 72(6):5093-8. PubMed ID: 9573280
[TBL] [Abstract][Full Text] [Related]
36. Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1.
Smith M; Salomon H; Wainberg MA
Clin Invest Med; 1994 Jun; 17(3):226-43. PubMed ID: 7523016
[TBL] [Abstract][Full Text] [Related]
37. The antiretroviral and cytostatic activity, and metabolism of 3'-azido-2',3'-dideoxythymidine, 3'-fluoro-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly cell type-dependent.
Balzarini J; Matthes E; Meeus P; Johns DG; De Clercq E
Adv Exp Med Biol; 1989; 253B():407-13. PubMed ID: 2558542
[No Abstract] [Full Text] [Related]
38. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
[TBL] [Abstract][Full Text] [Related]
39. Cross-resistance of dideoxycytidine-resistant cell lines to azidothymidine.
Agarwal RP; Wang W; Yo P; Han T; Fernandez M
Biochem Pharmacol; 1999 Nov; 58(10):1603-8. PubMed ID: 10535751
[TBL] [Abstract][Full Text] [Related]
40. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.
McLeod GX; McGrath JM; Ladd EA; Hammer SM
Antimicrob Agents Chemother; 1992 May; 36(5):920-5. PubMed ID: 1510414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
